Both IDH1 and IDH2 are somatically mutated in AML predominantly showing hotspot mutations [31,364,365], colon cancer [366], glioma [30], enchondromas [367,368], spindle cell hemangiomas [367], osteosarcoma [369], glioblastoma [27], chondrosarcomas [368], intrahepatic cholangiocarcinoma [370], prostate cancer, and B-acute lymphoblastic leukemia [371]. Here, IDH1 is linked to acute myeloid leukemia.